ECTRIMS 2019

Pharma

Roche's Ocrevus, given early, cuts wheelchair risk by 42%: study

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.
Carly Helfand Sep 13, 2019 11:52am

Novartis' reinvented leukemia drug bests Sanofi's Aubagio in MS

Sep 13, 2019 11:18am

Merck KGaA touts Mavenclad data as MS new drug race heats up

Sep 13, 2019 11:08am

Novartis' Mayzent delays wheelchair use by 4 years: analysis

Sep 12, 2019 12:26pm

Biogen's Tecfidera is safe, effective after 10-plus years: study

Sep 11, 2019 5:00am

Roche's Ocrevus combats biomarker that may spur MS progression

Sep 10, 2019 11:45am